SG10201508095UA - Humanized Anti-Epiregulin Antibody, And Cancer Therapeutic Agent Comprising Said Antibody As Active Ingredient - Google Patents
Humanized Anti-Epiregulin Antibody, And Cancer Therapeutic Agent Comprising Said Antibody As Active IngredientInfo
- Publication number
- SG10201508095UA SG10201508095UA SG10201508095UA SG10201508095UA SG10201508095UA SG 10201508095U A SG10201508095U A SG 10201508095UA SG 10201508095U A SG10201508095U A SG 10201508095UA SG 10201508095U A SG10201508095U A SG 10201508095UA SG 10201508095U A SG10201508095U A SG 10201508095UA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody
- active ingredient
- therapeutic agent
- humanized anti
- cancer therapeutic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011287654 | 2011-12-28 | ||
| JP2012133394 | 2012-06-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201508095UA true SG10201508095UA (en) | 2015-10-29 |
Family
ID=48697597
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201508095UA SG10201508095UA (en) | 2011-12-28 | 2012-12-28 | Humanized Anti-Epiregulin Antibody, And Cancer Therapeutic Agent Comprising Said Antibody As Active Ingredient |
| SG11201403565XA SG11201403565XA (en) | 2011-12-28 | 2012-12-28 | Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201403565XA SG11201403565XA (en) | 2011-12-28 | 2012-12-28 | Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9556264B2 (ja) |
| EP (1) | EP2799543A4 (ja) |
| JP (2) | JP6010551B2 (ja) |
| KR (1) | KR20140107610A (ja) |
| CN (1) | CN104136610B (ja) |
| AU (1) | AU2012361510B9 (ja) |
| BR (1) | BR112014015581A2 (ja) |
| CA (1) | CA2862254A1 (ja) |
| CL (1) | CL2014001730A1 (ja) |
| CO (1) | CO7101193A2 (ja) |
| CR (1) | CR20140352A (ja) |
| HK (1) | HK1200187A1 (ja) |
| IL (1) | IL233368A0 (ja) |
| MX (1) | MX350044B (ja) |
| MY (1) | MY172428A (ja) |
| PE (1) | PE20141560A1 (ja) |
| PH (1) | PH12014501468A1 (ja) |
| RU (1) | RU2634383C2 (ja) |
| SG (2) | SG10201508095UA (ja) |
| TW (1) | TWI593705B (ja) |
| UA (1) | UA115046C2 (ja) |
| WO (1) | WO2013100120A1 (ja) |
| ZA (1) | ZA201405405B (ja) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007312367B2 (en) | 2006-10-12 | 2012-09-06 | Chugai Seiyaku Kabushiki Kaisha | Diagnosis and treatment of cancer using anti-EREG antibody |
| JP5808052B2 (ja) | 2009-05-29 | 2015-11-10 | 中外製薬株式会社 | Ｅｇｆファミリーリガンドのアンタゴニストを成分とする医薬組成物 |
| CA2839539C (en) | 2011-06-30 | 2021-06-08 | Chugai Seiyaku Kabushiki Kaisha | Heterodimerized polypeptide |
| WO2013062083A1 (ja) | 2011-10-28 | 2013-05-02 | ファーマロジカルズ・リサーチ プライベート リミテッド | 癌幹細胞特異的分子 |
| TWI593705B (zh) | 2011-12-28 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient |
| ES2876009T3 (es) | 2012-12-27 | 2021-11-11 | Chugai Pharmaceutical Co Ltd | Polipéptido heterodimerizado |
| CA2916362A1 (en) * | 2013-06-24 | 2014-12-31 | Masami Suzuki | Therapeutic agent comprising humanized anti-epiregulin antibody as active ingredient for non-small-cell lung carcinoma excluding adenocarcinoma |
| CA2935143C (en) * | 2013-12-27 | 2024-05-07 | Chugai Seiyaku Kabushiki Kaisha | Method for purifying antibody having low isoelectric point |
| KR20160147855A (ko) * | 2014-05-01 | 2016-12-23 | 제넨테크, 인크. | 항-인자 d 항체 변이체 및 이의 용도 |
| JP6858559B2 (ja) | 2014-08-20 | 2021-04-14 | 中外製薬株式会社 | 蛋白質溶液の粘度測定方法 |
| JP2019202936A (ja) * | 2016-08-17 | 2019-11-28 | 中外製薬株式会社 | 抗Ｅｐｉｒｅｇｕｌｉｎ抗体と抗ＥＧＦＲ抗体との併用医薬 |
| WO2018155611A1 (ja) | 2017-02-24 | 2018-08-30 | 中外製薬株式会社 | 薬学的組成物、抗原結合分子、治療方法、およびスクリーニング方法 |
| CA3063344A1 (en) * | 2017-05-23 | 2018-11-29 | Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) | Novel cd73 antibody, preparation and uses thereof |
| GB201803892D0 (en) * | 2018-03-12 | 2018-04-25 | Ultrahuman Six Ltd | C-met binding agents |
| JP7523349B2 (ja) | 2018-08-29 | 2024-07-26 | 中外製薬株式会社 | 抗体半分子、および抗体半分子のホモ二量体形成を抑制する方法 |
| US20220089770A1 (en) * | 2019-01-24 | 2022-03-24 | Chugai Seiyaku Kabushiki Kaisha | Novel cancer antigens and antibodies of said antigens |
| JP7232707B2 (ja) | 2019-05-21 | 2023-03-03 | トーソー株式会社 | ブラケット構造 |
| CN112574308A (zh) | 2019-09-30 | 2021-03-30 | 和铂医药(苏州)有限公司 | 靶向bcma的抗体、双特异性抗体及其用途 |
| CN113150155B (zh) * | 2021-04-22 | 2022-04-08 | 安徽瀚海博兴生物技术有限公司 | 一种抗pd-l1人源化单克隆抗体及其应用 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5190858A (en) | 1989-02-01 | 1993-03-02 | Oncogene Science, Inc. | Monoclonal antibodies directed to epitopes of human transforming growth factor--α and uses thereof |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP0546073B1 (en) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| DE69233782D1 (de) | 1991-12-02 | 2010-05-20 | Medical Res Council | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
| AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2131151A1 (en) | 1992-03-24 | 1994-09-30 | Kevin S. Johnson | Methods for producing members of specific binding pairs |
| JPH07509137A (ja) | 1992-07-24 | 1995-10-12 | セル ジェネシス，インク． | 異種抗体の生産 |
| US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
| JPH08509612A (ja) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| US5783417A (en) | 1993-06-04 | 1998-07-21 | Taisho Pharmaceutical Co., Ltd. | Human-derived tumor cell growth inhibitors |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| AU690171B2 (en) | 1993-12-03 | 1998-04-23 | Medical Research Council | Recombinant binding proteins and peptides |
| EP0770628B9 (en) | 1994-07-13 | 2007-02-28 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6172213B1 (en) | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
| US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
| PL343322A1 (en) | 1998-04-03 | 2001-08-13 | Chugai Pharmaceutical Co Ltd | Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody |
| EP2261229A3 (en) | 1998-04-20 | 2011-03-23 | GlycArt Biotechnology AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| ES2568899T3 (es) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
| PT1189641E (pt) | 1999-06-25 | 2009-11-04 | Genentech Inc | Anticorpos anti-erbb2 humanizados e tratamento com anticorpos anti-erbb2 |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| EP3690043A1 (en) | 2000-10-06 | 2020-08-05 | Kyowa Kirin Co., Ltd. | Antibody composition-producing cell |
| CU22979A1 (es) | 2000-12-08 | 2004-09-09 | Centro Inmunologia Molecular | Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina |
| EP1383800A4 (en) | 2001-04-02 | 2004-09-22 | Idec Pharma Corp | RECOMBINANT ANTIBODIES CO-EXPRESSED WITH GNTIII |
| EP1464702A4 (en) | 2001-12-28 | 2005-09-21 | Chugai Pharmaceutical Co Ltd | METHOD FOR PROTEIN STABILIZATION |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| WO2003104453A1 (ja) | 2002-06-05 | 2003-12-18 | 中外製薬株式会社 | 抗体作製方法 |
| ES2263984T3 (es) | 2002-06-28 | 2006-12-16 | Domantis Limited | Ligandos doble-especificos con una vida media serica aumentada. |
| ATE541857T1 (de) | 2002-09-27 | 2012-02-15 | Xencor Inc | Optimierte fc-varianten und herstellungsverfahren dafür |
| EP1587921B1 (en) * | 2003-01-22 | 2010-07-28 | GlycArt Biotechnology AG | Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function |
| EP1607404A4 (en) | 2003-03-14 | 2008-01-23 | Taisho Pharmaceutical Co Ltd | MONOCLONAL ANTIBODY AND HYBRIDOM THAT PRODUCES THIS |
| US7195764B2 (en) | 2003-04-14 | 2007-03-27 | Arius Research Inc. | Cancerous disease modifying antibodies |
| JP5422101B2 (ja) | 2004-01-07 | 2014-02-19 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用 |
| MX350383B (es) | 2004-01-09 | 2017-09-04 | Pfizer | Anticuerpos contra madcam. |
| EP1706424B1 (en) | 2004-01-12 | 2009-07-22 | Applied Molecular Evolution, Inc. | Fc region variants |
| EP1747284A4 (en) | 2004-02-06 | 2009-03-11 | Wyeth Corp | DIAGNOSTICS AND THERAPEUTICS OF CANCER |
| PL1776384T3 (pl) | 2004-08-04 | 2013-10-31 | Mentrik Biotech Llc | WARIANTY REGIONÓW Fc |
| WO2006023420A2 (en) | 2004-08-16 | 2006-03-02 | Medimmune, Inc. | Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity |
| CA2577133A1 (en) | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
| WO2007024249A2 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
| EP1829961A4 (en) | 2004-12-22 | 2008-06-04 | Chugai Pharmaceutical Co Ltd | PROCESS FOR PREPARING ANTIBODY USING A CELL WHOSE FUCOSE CARRIER FUNCTION IS INHIBITED |
| JP2008527978A (ja) | 2005-01-11 | 2008-07-31 | モレキュラー ロジックス，インコーポレイテッド | Ｐａｎ−ＨＥＲアンタゴニストおよび使用方法 |
| EP1871808A2 (en) | 2005-03-31 | 2008-01-02 | Xencor, Inc. | Fc VARIANTS WITH OPTIMIZED PROPERTIES |
| CA2606102C (en) | 2005-04-26 | 2014-09-30 | Medimmune, Inc. | Modulation of antibody effector function by hinge domain engineering |
| US9006240B2 (en) | 2005-08-02 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
| SI1919503T1 (sl) | 2005-08-10 | 2015-02-27 | Macrogenics, Inc. | Identifikacija in inĺ˝eniring protiteles z variantnimi fc regijami in postopki za njih uporabo |
| AU2006299429B2 (en) | 2005-10-03 | 2012-02-23 | Xencor, Inc. | Fc variants with optimized Fc receptor binding properties |
| EP2010665A4 (en) | 2006-02-08 | 2010-10-27 | Targeted Molecular Diagnostics | BURIENT ERBB LIGAND BINDING MOLECULES AND METHODS FOR THEIR PREPARATION AND USE |
| DK3056568T3 (da) | 2006-03-31 | 2021-11-01 | Chugai Pharmaceutical Co Ltd | Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik |
| AU2007312367B2 (en) | 2006-10-12 | 2012-09-06 | Chugai Seiyaku Kabushiki Kaisha | Diagnosis and treatment of cancer using anti-EREG antibody |
| PL2099826T3 (pl) | 2007-01-05 | 2014-04-30 | Univ Zuerich | Przeciwciało przeciwko beta-amyloidowi i jego zastosowania |
| WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
| JP2009078946A (ja) | 2007-09-26 | 2009-04-16 | Fujifilm Corp | コア−シェル型金属酸化物粒子及びその製造方法 |
| SG193868A1 (en) | 2007-09-26 | 2013-10-30 | Chugai Pharmaceutical Co Ltd | Modified antibody constant region |
| AR066172A1 (es) | 2007-09-28 | 2009-07-29 | Chugai Pharmaceutical Co Ltd | Metodo para la preparacion de un anticuerpo antiglipicano 3 con modulada cinetica plasmatica mediante variacion de la semivida plasmatica. |
| JP5808052B2 (ja) | 2009-05-29 | 2015-11-10 | 中外製薬株式会社 | Ｅｇｆファミリーリガンドのアンタゴニストを成分とする医薬組成物 |
| GB0909904D0 (en) | 2009-06-09 | 2009-07-22 | Affitech As | Product |
| GB0909906D0 (en) * | 2009-06-09 | 2009-07-22 | Affitech As | Antibodies |
| EP2626414B1 (en) | 2010-10-06 | 2020-07-15 | Chugai Seiyaku Kabushiki Kaisha | Cancer stem cell mass and process for production thereof |
| CA2839539C (en) * | 2011-06-30 | 2021-06-08 | Chugai Seiyaku Kabushiki Kaisha | Heterodimerized polypeptide |
| TWI593705B (zh) | 2011-12-28 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient |
| CA2916362A1 (en) | 2013-06-24 | 2014-12-31 | Masami Suzuki | Therapeutic agent comprising humanized anti-epiregulin antibody as active ingredient for non-small-cell lung carcinoma excluding adenocarcinoma |
-
2012
- 2012-12-26 TW TW101150028A patent/TWI593705B/zh not_active IP Right Cessation
- 2012-12-28 US US14/369,539 patent/US9556264B2/en not_active Expired - Fee Related
- 2012-12-28 MX MX2014008009A patent/MX350044B/es active IP Right Grant
- 2012-12-28 SG SG10201508095UA patent/SG10201508095UA/en unknown
- 2012-12-28 RU RU2014130766A patent/RU2634383C2/ru not_active IP Right Cessation
- 2012-12-28 BR BR112014015581-0A patent/BR112014015581A2/pt not_active IP Right Cessation
- 2012-12-28 KR KR20147020786A patent/KR20140107610A/ko not_active Application Discontinuation
- 2012-12-28 UA UAA201408353A patent/UA115046C2/uk unknown
- 2012-12-28 SG SG11201403565XA patent/SG11201403565XA/en unknown
- 2012-12-28 JP JP2013551852A patent/JP6010551B2/ja not_active Expired - Fee Related
- 2012-12-28 MY MYPI2014701733A patent/MY172428A/en unknown
- 2012-12-28 PE PE2014001036A patent/PE20141560A1/es not_active Application Discontinuation
- 2012-12-28 AU AU2012361510A patent/AU2012361510B9/en not_active Ceased
- 2012-12-28 CA CA2862254A patent/CA2862254A1/en not_active Abandoned
- 2012-12-28 EP EP12863154.6A patent/EP2799543A4/en not_active Withdrawn
- 2012-12-28 CN CN201280070788.2A patent/CN104136610B/zh not_active Expired - Fee Related
- 2012-12-28 WO PCT/JP2012/084042 patent/WO2013100120A1/ja active Application Filing
-
2014
- 2014-06-25 IL IL233368A patent/IL233368A0/en unknown
- 2014-06-25 PH PH12014501468A patent/PH12014501468A1/en unknown
- 2014-06-26 CL CL2014001730A patent/CL2014001730A1/es unknown
- 2014-07-22 ZA ZA2014/05405A patent/ZA201405405B/en unknown
- 2014-07-22 CR CR20140352A patent/CR20140352A/es unknown
- 2014-07-24 CO CO14161083A patent/CO7101193A2/es unknown
-
2015
- 2015-01-16 HK HK15100507.9A patent/HK1200187A1/xx not_active IP Right Cessation
-
2016
- 2016-09-15 US US15/266,829 patent/US20170129950A1/en not_active Abandoned
- 2016-09-16 JP JP2016181435A patent/JP6329601B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1200187A1 (en) | Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient | |
| HK1203309A1 (en) | Antibody drug conjugates and related compounds, compositions, and methods | |
| IL231386A0 (en) | Pyrazoloquinolinone derivatives, their preparation and medical use | |
| IL228738B (en) | Antibody against cldn6, a pharmaceutical preparation including it and its use | |
| BR112014009634A2 (pt) | preparação e agente terapêutico | |
| EP2868667A4 (en) | THERAPEUTIC FOR ANEMIA, INCLUDING NICE ENAMA AND CANCER-INDUCED ANEMIA WITH ANTI-BMP9 ANTIBODY AS ACTIVE AGENT | |
| SG2014008304A (en) | C10rf32 antibodies, and uses thereof for treatment of cancer | |
| EP2792746A4 (en) | OLIGONUCLEOTIDE AND THERAPEUTIC FOR HYPERLIPIDEMIA WITH THIS AS AN ACTIVE SUBSTANCE | |
| EP2773637A4 (en) | BENZOLSULFONAMIDE COMPOUNDS AND THEIR USE AS MEDICAMENTS | |
| ZA201209145B (en) | Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application | |
| EP3741772C0 (en) | PREPARATIONS OF HYDROPHOBIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE AND USE | |
| EP2666475A4 (en) | THERAPEUTIC AGENT FOR ALOPECIA | |
| ZA201308186B (en) | Solid, particulate tanning agent preparations | |
| IL227558A0 (en) | A therapeutic agent for tumors | |
| IL231444A0 (en) | Aniline derivatives, their preparation and medical application | |
| EP2729008A4 (en) | SYSTEMS, METHODS AND FORMULATIONS FOR THE TREATMENT OF CANCER | |
| HK1223567A1 (zh) | 含有人源化抗上皮調節蛋白抗體作爲有效成分的腺癌以外的非小細胞肺癌的治療藥 | |
| IL233238A0 (en) | Sulphonylaminopyrrolidinone derivatives, their preparation and therapeutic use | |
| ZA201408566B (en) | Anti-human cd69 antibody, and use thereof for medical purposes | |
| HK1215959A1 (zh) | 人源化抗體、其藥劑偶聯物以及它們的用途 | |
| IL220859A0 (en) | Alkyl-heterocycle-carbamate derivatives, their preparation and therapeutic application | |
| EP2781521A4 (en) | NOVEL COMPOUND OF SPIROINDOLINE AND THERAPEUTIC AGENT CONTAINING THE SAME | |
| IL232339A0 (en) | 32rf10c antibodies, and their uses for cancer treatment | |
| BR112014005011A2 (pt) | composto, métodos de tratamento e composição farmacêutica |